Researchers discovered that visual experience triggers changes in brain protein expression, which enhances learning and processing of sensory information in tadpoles. This finding suggests a possible new role for proteins in sensory processing in people with autism spectrum disorder.
The Scripps Research team will expand studies on broadly neutralizing antibodies that can neutralize many strains of malaria and influenza. The grant aims to design promising vaccine candidates against these diseases, which kill millions globally each year.
The program aims to collect unprecedented health data from one million participants, enabling scientists to study individual differences in biology and lifestyle. The initiative will provide insights into how factors like genetics, exercise habits, and environment impact human health.
The Scripps Translational Science Institute has received a renewed $34 million funding from the National Institutes of Health to advance individualized medicine through genomic and digital technologies. The institute will form partnerships with other institutions to improve translational research and train future leaders in biomedicine.
Researchers at Scripps Research Institute will study genetic factors behind oxycodone and cocaine addiction using a unique, genetically diverse rat model. The five-year grants will allow for the creation of shared tissue banks for researchers worldwide to use in addiction studies.
Scientists at Scripps Research Institute have identified a protein called GPR68 that senses blood flow and tells small blood vessels to dilate. This discovery could lead to new treatments for conditions like ischemic stroke and hypertension.
Researchers found that a transcription factor protein called Runx3 plays a critical role in directing T cells towards memory cells, which can live for decades. This discovery may lead to the development of drugs that improve immune responses to vaccines and treatments for chronic diseases such as cancer.
Researchers aim to eradicate chronic lymphocytic leukemia (CLL) by targeting specific cancer cells. The team has discovered a binding site on CLL lymphocytes that pulls antibodies into the cells in minutes, allowing for more effective treatments.
Researchers found that a protein called myosin IIA contracts to give red blood cells their distinctive dimpled shape, shedding light on sickle cell diseases and other disorders. The discovery could lead to new treatments for conditions where red blood cells are deformed.
Scientists at Scripps Research Institute discovered a new aspect of the flu virus and its interaction with antibodies in the lungs. They found that IgA antibodies can protect against infections through two different ways.
A genetic mutation in the PIEZO1 gene may protect people from malaria by dehydrating red blood cells, a condition previously thought to be extremely rare. The mutation is found to be common in African populations, suggesting an evolutionary adaptation to malaria.
Researchers at TSRI found that cells activate protective pathways during stress, leading to longer mitochondria and improved energy production. This mechanism may help combat stress and age-related diseases.
Researchers at TSRI have developed a new desulfonylative cross-coupling reaction that simplifies the synthesis of drug-like molecules, including alkyl-fluorinated compounds. This method paves the way for creating new types of compounds and facilitating the synthesis of pharmaceuticals.
Researchers at TSRI have discovered a path to treating Charcot-Marie-Tooth disease subtype CMT2D by restoring normal protein function in the nervous system using a small molecule. The study reveals that mutant protein interactions with HDAC6 are responsible for nerve damage, and blocking this interaction can restore proper nerve function.
Researchers at TSRI have discovered a toxic protein that travels to mitochondria, causing damage and leading to the loss of dopamine-producing neurons. This finding offers new insights into the mechanisms underlying Parkinson's disease.
Researchers at TSRI have discovered that individuals with high levels of the enigmatic receptor GPR158 may be more susceptible to depression following chronic stress. This finding provides a potential clue to why some people are more resilient against mental illness, and offers a new target for developing effective treatments.
The Scripps Research Institute has developed a new method for creating glycan arrays that can be used to study the interactions between glycans and proteins. The breakthrough, published in Nature Communications, uses enzymes naturally produced by cells to create branching glycans.
Researchers used fruit fly hybrids to discover the proteome's plasticity during development, which may provide insights into rapid phenotypic variation and disease mechanisms. The study also sheds light on how proteins interact with each other and how the proteostasis network coordinates protein synthesis, folding, and degradation.
Researchers at Scripps Research Institute developed a quick method to modify dozens of drugs or molecules, improving disease-fighting properties. The approach, called click chemistry, was found to increase the potency of three cancer drugs under lab conditions.
A Phase 2 clinical trial shows that patients with acute ischemic stroke can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug. The treatment also substantially reduced cerebral hemorrhage in patients.
Researchers will collect data from survivors of viral outbreaks to understand how some people fight off the disease. The goal is to inform vaccine design, develop new diagnostics, and prevent future outbreaks.
Researchers found FOXO proteins maintain healthy cartilage and prevent joint degeneration. Targeting FoxO could develop new therapies to treat osteoarthritis.
Researchers at Scripps Research Institute have created a safe and effective vaccine to block heroin's lethal effects, using an adjuvant already approved by the FDA. The vaccine, which is stable at room temperature for up to 30 days, shows promise in treating heroin addiction and preventing overdose deaths.
A new study provides the first 3D visualization of the dynein-dynactin complex bound to microtubules, revealing a surprising feature: two dynein molecules where one was expected, with four motor domains total. This discovery helps explain how dynein can haul large loads over long distances in crowded cellular environments.
Researchers at The Scripps Research Institute (TSRI) have discovered that levels of a key protein called LTBP3 fuel the chain reaction leading to cancer spread. Lower LTBP3 levels are associated with better prognosis in patients with certain types of cancer, suggesting it as a potential 'upstream' drug target.
Researchers at The Scripps Research Institute identified the p53 gene as a master regulator of mesenchymal stem cells' ability to differentiate. The study found that a basal level of p53 is required for MSCs to act accurately in the body, and its deletion can lead to unexpected differentiation outcomes.
A new study from The Scripps Research Institute found that dietary xenoestrogens like zearalenone and genistein can reverse the effects of palbociclib/letrozole combination therapy for breast cancer. Exposure to these compounds may significantly reduce the effectiveness of anti-estrogen treatments.
Researchers at The Scripps Research Institute have discovered the workings of a promising treatment for Marburg virus, which has a mortality rate of up to 88 percent. The treatment, MR191, targets a conserved site on the virus and neutralizes it by mimicking the host receptor.
Researchers at Scripps Research Institute develop theory that chemical reactions supporting life today could have occurred with ingredients likely present on early Earth. The citric acid cycle's precursor, glyoxylate, is identified as a key molecule in these reactions.
Researchers at Scripps Research Institute use nuclear magnetic resonance spectroscopy to study the A2a adenosine receptor, revealing its dynamic structure and a
Scientists at Scripps Research Institute have solved the mystery of Piezo1's structure, revealing three curved blades that move in response to mechanical force. The findings point the way to targeting diseases where Piezo1 is mutated.
Researchers identified a mechanism where ileal Crohn's disease is induced by bile acids when T cell adaptation does not occur properly. Bile acid sequestrants may be an effective treatment for patients with impaired MDR1 expression, suggesting a potential new avenue for therapy.
Scientists uncovered new insights into the regulatory network behind axon termination, a crucial process in neuron development. The study found that RPM-1 signaling is required to regulate growth cone collapse and microtubule stability during axon termination.
Researchers at Scripps Research Institute find Runx3 protein enables killer T cells to accumulate in solid tumors, potentially improving cancer immunotherapy strategies. Enhancing Runx3 activity delays tumor growth and prolongs survival in mouse melanoma models.
Researchers at Scripps Research Institute have discovered a family of compounds, leinamycin (LNM), with potential as anti-cancer agents. By mining bacterial genomes, the team identified 49 bacteria with genes that code for LNM compounds, offering new avenues for cancer treatment.
Scientists at Scripps Research Institute found that taurine helps spark a process called remyelination, crucial for repairing nerve cells damaged in multiple sclerosis. Combining taurine with existing MS drugs and future remyelination-inducing treatments may improve overall efficacy.
Researchers at Scripps Research Institute and Duke University have made the first determination of TRPM8's atomic structure using cryo-electron microscopy. The findings reveal unexpected binding pocket locations for menthol and other cold-sensing molecules, opening new avenues for drug development.
A new technique, ligand-accelerated non-directed C-H functionalization, enables the late-stage modification of complex drug molecules to improve therapeutic properties. Researchers used a special ligand molecule called 2-pyridone to enhance palladium's reactivity with targeted C-H bonds.
Researchers found that a specific G protein linked to dopamine receptors plays a role in both forming and erasing memories. The study suggests that the brain has an 'optimization process' that whittles away unnecessary memories, allowing for better function.
Researchers from TSRI have identified a process in nerve cells called the S-nitrosylation reaction that may contribute to Parkinson's disease. The study found that this reaction can trigger cell death by preventing the proper removal of damaged mitochondria, leading to neuronal damage and death.
Scientists at Scripps Research Institute developed new opioid pain relievers that are as potent as morphine but do not slow or stop breathing, reducing the risk of overdose. The compounds show a spectrum of bias between signaling pathways, providing an opportunity to expand the therapeutic window and administer drugs safely.
Scientists provide detailed picture of how human antibodies bind to malaria parasite's circumsporozoite protein, a key target for vaccine development. The study could lead to enhanced efficacy and duration of protection against malaria.
Researchers have tested a potential new drug, NitroSynapsin, in a mouse model of an autism disorder and found it largely corrected electrical, behavioral and brain abnormalities. The candidate drug is intended to restore the signaling imbalance found in virtually all forms of autism spectrum disorder.
Ozanimod demonstrated a significant reduction in new or enlarging T2 lesions over one year, as well as slowed brain volume loss, compared to Avonex in patients with relapsing multiple sclerosis. The findings pave the way for ozanimod to enter the New Drug Approval process with the FDA.
Researchers at Scripps Research Institute have discovered a compound that irreversibly stops the growth of certain aggressive, treatment-resistant tumor cells. The compound, FiVe1, blocks cell division by binding to a structural protein, vimentin, produced abundantly in mesenchymal-type cells.
Researchers at Scripps Research Institute identify diamidophosphate (DAP) as a potential 'missing link' in chemistry that led to the emergence of life. DAP can phosphorylate key ingredients in early life forms, leading to the formation of primitive cells and potentially kick-starting life on Earth.
A new study from Scripps Research Institute reveals that egg-based production causes the virus to target bird cells, disrupting the major antibody target site on the surface. This mutation renders the flu vaccine less effective in humans, with recent vaccines proving only 33% effective against H3N2 viruses.
A new class of antibody-drug conjugates, dubbed dual variable domain antibodies (DVD-ADCs), have been developed using a versatile double-decker technology. These pharmaceuticals selectively deliver drugs to cancer cells without harming healthy cells and tissues.
Scientists from Scripps Research Institute have shown that a novel compound effectively suppresses HIV virus production in chronically infected cells and prevents viral rebound. The 'block-and-lock' approach blocks reactivation of the virus in cells and locks it into a durable state of latency.
Researchers used advanced mass spectrometry technology to create a molecular model that can aid in designing new osteoporosis treatments. The study's findings provide insights into the structure of a key receptor regulating calcium levels, paving the way for more effective and safer therapies.